Elscint begat a new spiral CT family last month with the introductionof three volumetric scanners positioned underneath the vendor'spremium CT Twin system. The move was in part a recognition ofsystem price constraints in the European market. Elscint
Elscint begat a new spiral CT family last month with the introductionof three volumetric scanners positioned underneath the vendor'spremium CT Twin system. The move was in part a recognition ofsystem price constraints in the European market. Elscint exhibitedthe expanded CT line at the European Congress of Radiology conferencein Vienna.
Two of the new scanners, Helicat and Helicat II, are single-detectorsystems positioned to compete with the bulk of spiral CT offeringson the market. The third scanner, CT Twin II, is a lower pricedversion of the dual-detector CT Twin.
CT Twin II trims system cost compared to the Twin through areduction in some technical specifications, such as a lower heatcapacity tube. All Elscint spiral units use the same hardwareand software architecture as the Twin, however, and may be upgradedto the premium system.
Elscint entered the spiral CT market two years ago with allits technological guns firing (SCAN 2/12/92). The CT Twin's dualsolid-state detector design was--and remains--unique in the market.By acquiring two slices during one cycle of the continuously rotatingx-ray gantry and tube, users scan volumes faster than with single-detectorspiral systems of comparable cycle times. This allows for thecoverage of a larger area during single-breath-hold exams. Dualacquisition also offers savings potential through reduced tubeusage per volume scanned.
Although the CT Twin technology was attractive, its high-endprice tag remained out of reach for many customers. European capson capital acquisitions combined with the general recession andcurrency devaluations in several markets convinced Elscint ofthe need to provide lower end alternatives to the Twin in CT,according to Jonathan Adereth, Elscint vice president of sales.
"The Twin II and Helicat II are derivative of the situationin the European market," he told SCAN. "When we initiallyintroduced the Twin, we did not intend to introduce a lower endversion. As is normally the case with a premium product, we introducedit with the full range of options and features. In Europe, however,while there was a wish to buy it, the cost was exceeding availablebudgets."
Worldwide as well as in Europe, Elscint's investment in CTdevelopment over the last several years has proven fruitful. Demandfor CT has kept up relative to other medical imaging modalities.
"Contrary to many of our competitors and industry analysts,we predicted five years ago that CT was not going to decline dueto the introduction of MRI," said Dan Inbar, Elscint vicepresident of marketing. "We saw a continued need (for CTservices) from the referral base. This proved to be true, especiallyduring this year when there has been some decline in the worldMRI market but no decline at all in the CT market."
Elscint has seen strong demand for the Twin in Europe and elsewhere--despiteits price. Over 20 units have been sold in France, Adereth said.The vendor shipped its first Helicat to Canada last month andhas three European deliveries scheduled in France and Germany.
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.